Medical Access and Reimbursement in Greece

Currently classified as a strictly controlled psychotropic/illegal substance under Greek narcotics law (Law 4139/2013) with no authorised medical marketing authorisation or routine reimbursement; authorised access is limited to formal clinical research approved by competent authorities. Currently there is no national regulatory framework in Greece that permits prescribing or reimbursing psilocybin outside of approved clinical trials. # #

Currently classified as a strictly controlled substance under Greek drug‑control law (Law 4139/2013) with no authorised medical marketing authorisation or public reimbursement for MDMA‑assisted therapy; permitted medical access is limited to approved clinical research protocols and compassionate use only if separately authorised by national competent authorities. Routine outpatient prescribing or reimbursement does not exist. # #

Esketamine nasal spray (Spravato) has a European marketing authorisation and therefore may be marketed and used in EU member states including Greece under the conditions of the EU/EMA authorisation; the EMA authorisation details the indication (treatment‑resistant major depressive disorder, used under supervised administration) and the special safety/monitoring requirements. #

In practice, availability and reimbursement in Greece follow the national pricing/reimbursement and hospital/clinic procurement routes: because Spravato is an EMA‑authorised medicine it may be imported/placed on the Greek market subject to national marketing‑authorisation holder arrangements and hospital/pharmacy supply rules, but widespread public reimbursement is not automatic—reimbursement requires evaluation by Greek health authorities and inclusion on national reimbursement lists (positive pricing/reimbursement decisions). (See: Greek national medicines/health technology assessment and hospital procurement pathways for EMA‑authorised medicines.) #

Ketamine is an authorised medicine in Greece for anaesthesia and key medical indications and is used routinely in hospitals for surgical and acute care (therefore reimbursed within standard hospital care when used for licensed indications). Outside anaesthesia, ketamine is commonly used off‑label in private psychiatric settings for treatment‑resistant depression and acute suicidality, typically as intravenous/infusion treatments provided by private clinics; such off‑label psychiatric use is not a nationally standardised, routinely publicly reimbursed treatment and is generally paid for privately unless explicitly accepted into a hospital protocol with prior approval.

Greek regulation recognises off‑label prescribing under specific procedural controls and potential reimbursement pathways if included in approved therapeutic protocols (see discussion of off‑label regulation and reimbursement procedures). Physicians who prescribe off‑label must follow national off‑label authorisation procedures for reimbursement when applicable. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Although there are private operators advertising ibogaine treatment services in Greece, these operate outside any formal national authorisation framework and do not constitute legal, reimbursed medical provision. Exercise caution and verify legal/clinical authorisations locally. # #

Currently classified as a strictly controlled substance under national drug scheduling laws (components such as DMT are scheduled); there is no authorised medical use or routine reimbursement for ayahuasca in Greece outside of approved clinical research or very narrow, legally sanctioned exceptions. Religious/sacramental claims do not provide a general legal medical pathway. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline (and cacti containing mescaline) remains scheduled and unavailable for reimbursed medical treatment in Greece. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Substituted phenethylamines (2C‑series) are included in national control frameworks and are not available for medical prescribing or reimbursement. #